• BioXcel Therapeutics Inc BTAI.OQ reported a quarterly adjusted loss of 32 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.72. The mean expectation of six analysts for the quarter was for a loss of 54 cents per share. Wall Street expected results to range from -73 cents to -44 cents per share.

• Revenue fell 37.2% to $214.00 thousand from a year ago; analysts expected $1.31 million.

• BioXcel Therapeutics Inc's reported EPS for the quarter was a loss of 32 cents​.

• The company reported a quarterly loss of $13.65 million.

• BioXcel Therapeutics Inc shares had risen by 1.5% this quarter and lost 79.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.7% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for BioXcel Therapeutics Inc is 6.00

This summary was machine generated from LSEG data November 14 at 08:58 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)